The American Academy of Neurology formally recommended oral cannabis extract for MS spasticity and pain (Level A), with Sativex recommended for spasticity symptoms, pain, and urinary frequency (Level B).
Read this if you have MS and want the official neurological guidelines on cannabis-based treatments.
Level A (highest evidence): oral cannabis extract for MS spasticity symptoms and pain
What the researchers found
This is the full guideline publication (not the commentary). Key recommendations:
Level A (established): Clinicians might offer oral cannabis extract for spasticity symptoms and pain (excluding central neuropathic pain).
Level B (probable): THC for spasticity symptoms and pain; Sativex for spasticity symptoms, pain, and urinary frequency. These agents are probably ineffective for objective spasticity (short-term) and tremor. Sativex probably ineffective for objective spasticity and urinary incontinence.
Level C (possible): Cannabis agents possibly effective long-term for spasticity and pain.
The guidelines emphasize that cannabinoids may cause adverse effects and that clinicians should exercise caution regarding standardized versus non-standardized preparations and overall quality control.
Why it matters
This is the definitive AAN guideline on complementary and alternative medicine in MS, setting the standard of care for cannabis-based treatments in neurology practice. Its systematic methodology and graded recommendations provide clear clinical guidance.
The numbers in context
Literature searched: 1970-September 2013. Level A: oral cannabis extract for spasticity symptoms/pain. Level B: THC and Sativex for symptoms/pain; ineffective for objective measures. Safety/efficacy of CAM interaction with MS disease-modifying therapies: unknown.
How the study worked
Systematic literature review from 1970 to September 2013, with articles classified according to AAN evidence standards. Recommendations were graded based on evidence strength (Level A through Level C). The guideline development subcommittee included experts in MS, neurology, and evidence-based medicine.
What this study cannot tell us
The literature search ended in September 2013 and does not include subsequent studies. U.S. access to standardized cannabis preparations remains limited. The guidelines acknowledge unknown interactions between cannabis and MS disease-modifying therapies. The distinction between subjective and objective outcomes creates clinical ambiguity.
How to read the evidence
This is the official systematic evidence-based guideline from the American Academy of Neurology, the highest tier of clinical evidence synthesis.
When this study was published
Published in 2014. These guidelines remain influential, though the evidence base has continued to grow.
The bigger picture
These guidelines changed the conversation about cannabis in neurology from fringe therapy to evidence-based recommendation. The careful distinction between what cannabis can and cannot do for MS, supported by systematic evidence review, provides a model for how cannabis should be integrated into medical practice.
Questions still open
- How should these guidelines be applied in states where medical cannabis is legal but unregulated? Do newer studies change any of the recommendations? Should objective or subjective outcomes be prioritized in clinical decision-making?
Common questions
What is the difference between Level A, B, and C recommendations?
Can I use dispensary cannabis based on these guidelines?
Read the original research
Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology.
Neurology, 82(12), 1083-92
Citation
Yadav, Vijayshree; Bever, Christopher; Bowen, James; Bowling, Allen; Weinstock-Guttman, Bianca; Cameron, Michelle; Bourdette, Dennis; Gronseth, Gary S; Narayanaswami, Pushpa. (2014). Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology.. Neurology, 82(12), 1083-92. https://doi.org/10.1212/WNL.0000000000000250
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk